Reserpine

Overview

Reserpine is a drug that is used for the treatment of high blood pressure, usually in combination with a thiazide diuretic or vasodilator. Large clinical trials have shown that combined treatment with reserpine plus a thiazide diuretic reduces mortality of people with hypertension. Although the use of reserpine as a solo drug has declined since it was first approved by the FDA in 1955, the combined use of reserpine and a thiazide diuretic or vasodilator is still recommended in patients who do not achieve adequate lowering of blood pressure with first-line drug treatment alone. The reserpine-hydrochlorothiazide combo pill was the 17th most commonly prescribed of the 43 combination antihypertensive pills available in 2012.[1–6] WP

The antihypertensive actions of reserpine are largely due to its antinoradrenergic effects, which are a result of its ability to deplete catecholamines (among other monoamine neurotransmitters) from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral vascular resistance.[7] WP

At doses of 0.05 to 0.2 mg per day, reserpine is well tolerated; the most common adverse effect being nasal stuffiness.[8] WP

Reserpine has also been used for relief of psychotic symptoms. A review found that in persons with schizophrenia, reserpine and chlorpromazine had similar rates of adverse effects, but that reserpine was less effective than chlorpromazine for improving a person's global state.[9][10] WP

Uses, dosage and effects

Medical uses

Reserpine is recommended as an alternative drug for treating hypertension by the JNC 8. A 2016 Cochrane review found reserpine to be as effective as other first-line antihypertensive drugs for lowering of blood pressure. The reserpine–thiazide diuretic combination is one of the few drug treatments shown to reduce mortality in randomized controlled trials: The Hypertension Detection and Follow-up Program, the Veterans Administration Cooperative Study Group in Anti-hypertensive Agents, and the Systolic Hypertension in the Elderly Program. Moreover, reserpine was included as a secondary antihypertensive option for patients who did not achieve blood pressure lowering targets in the ALLHAT study.[3][11–15] WP

The daily dose in antihypertensive treatment is as low as 0.05 to 0.25 mg. WP

Reserpine was previously used to treat symptoms of dyskinesia in patients with Huntington's disease, but alternative medications are preferred today.[16][17] WP

The use of reserpine as an antipsychotic drug had been nearly completely abandoned, but more recently it made a comeback as adjunctive treatment, in combination with other antipsychotics, so that more refractory patients get dopamine blockade from the other antipsychotic, and dopamine depletion from reserpine. Doses for this kind of adjunctive goal can be kept low, resulting in better tolerability. Originally, doses of 0.5 mg to 40 mg daily were used to treat psychotic diseases. WP

Doses in excess of 3 mg daily often required combined administration with an anticholinergic drug to combat excessive cholinergic activity in many parts of the body, as well as parkinsonism. For adjunctive treatment, doses are typically kept at or below 0.25 mg twice a day. WP

Veterinary use

Reserpine is used as a long-acting tranquilizer to subdue excitable or difficult horses and has been used illicitly for the sedation of show horses, for-sale horses, and in other circumstances where a "quieter" horse might be desired.[18] WP

It is also used in dart guns. WP

Antibacterial effects

Reserpine inhibits formation of biofilms by Staphylococcus aureus and inhibits the metabolic activity of bacteria present in biofilms.[19] WP

Risks and side effects

Adverse effects

At doses of less than 0.2 mg/day, reserpine has few adverse effects, the most common of which is nasal congestion.[20] WP

Reserpine can cause: nasal congestion, nausea, vomiting, weight gain, gastric intolerance, gastric ulceration (due to increased cholinergic activity in gastric tissue and impaired mucosal quality), stomach cramps and diarrhea. The drug causes hypotension and bradycardia and may worsen asthma. Congested nose and erectile dysfunction are other consequences of alpha-blockade.[21] WP

Central nervous system effects at higher doses (0.5 mg or higher) include drowsiness, dizziness, nightmares, Parkinsonism, general weakness and fatigue.[22] WP

High dose studies in rodents found reserpine to cause fibroadenoma of the breast and malignant tumors of the seminal vesicles among others. Early suggestions that reserpine causes breast cancer in women (risk approximately doubled) were not confirmed. It may also cause hyperprolactinemia.[21] WP

Reserpine passes into breast milk and is harmful to breast-fed infants, and should therefore be avoided during breastfeeding if possible.[23] WP

It may produce an excessive decline in blood pressure at doses needed for treatment of anxiety, depression, or psychosis.[24] WP

Pharmacology

Mechanism of action

Reserpine irreversibly blocks the H⁺-coupled vesicular monoamine transporters, VMAT1 and VMAT2. VMAT1 is mostly expressed in neuroendocrine cells. VMAT2 is mostly expressed in neurons. Thus, it is the blockade of neuronal VMAT2 by reserpine that inhibits uptake and reduces stores of the monoamine neurotransmitters norepinephrine, dopamine, serotonin and histamine in the synaptic vesicles of neurons. VMAT2 normally transports free intracellular norepinephrine, serotonin, and dopamine in the presynaptic nerve terminal into presynaptic vesicles for subsequent release into the synaptic cleft ("exocytosis"). Unprotected neurotransmitters are metabolized by MAO (as well as by COMT), attached to the outer membrane of the mitochondria in the cytosol of the axon terminals, and consequently never excite the post-synaptic cell. Thus, reserpine increases removal of monoamine neurotransmitters from neurons, decreasing the size of the neurotransmitter pools, and thereby decreasing the amplitude of neurotransmitter release. As it may take the body days to weeks to replenish the depleted VMATs, reserpine's effects are long-lasting.[25][26][27] WP

Research

Animal model of depression and amotivation

Similarly to tetrabenazine, reserpine, via depletion of monoamine neurotransmitters, produces depression-like effects and lack of motivation or fatigue-like symptoms in animals. This can be useful in evaluating new antidepressants and psychostimulant-like agents.[28][29] WP

History

History

Reserpine was isolated in 1952 from the dried root of Rauvolfia serpentina (Indian snakeroot), which had been known as Sarpagandha and had been used for centuries in India for the treatment of insanity, as well as fever and snakebites — Mahatma Gandhi used it as a tranquilizer. It was first used in the United States by Robert Wallace Wilkins in 1950. Its molecular structure was elucidated in 1953 and natural configuration published in 1955. It was introduced in 1954, two years after chlorpromazine. The first total synthesis was accomplished by R. B. Woodward in 1958.[30–34] WP

Reserpine was influential in promoting the thought of a biogenic amine hypothesis of depression. Reserpine-induced depletion of monoamine neurotransmitters in the synapse allegedly caused depression and was cited as evidence that a "chemical imbalance", namely low levels of monoamine neurotransmitters, is what causes clinical depression in humans. A 2003 review showed barely any evidence that reserpine actually causes depression in either human patients or animal models. Notably, reserpine was the first compound ever to be shown to be an effective antidepressant in a randomized placebo-controlled trial. A 2022 systematic review found that studies of the influence of reserpine on mood were highly inconsistent, with similar proportions of studies reporting depressogenic effects, no influence on mood, and antidepressant effects. The quality of evidence was limited, and only a subset of studies were randomized controlled trials. Although reserpine itself cannot provide good evidence for the monoamine hypothesis of depression, other lines of evidence support the idea that boosting serotonin or norepinephrine can effectively treat depression, as shown by SSRIs, SNRIs, MAOIs and tricyclic antidepressants.[35–40] WP

Chemistry

Formula

C33H40N2O9 PC

CAS number

50-55-5 PC

Molar mass (g/mol)

608.7 PC

IUPAC name (computed by PubChem)

methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate PC

SMILES

CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC PC

InChIKey

QEVHRUUCFGRFIF-MDEJGZGSSA-N PC

PubChem CID

5770

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Tsioufis C, Thomopoulos C. Combination drug treatment in hypertension. Pharmacological Research. November 2017. doi:10.1016/j.phrs.2017.09.011 · PMID 28939201
2. Other Reserpine
3. Journal / agency James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. February 2014. doi:10.1001/jama.2013.284427 · PMID 24352797
4. Journal / agency Weir MR. Reserpine: A New Consideration of and Old Drug for Refractory Hypertension. American Journal of Hypertension. August 2020. doi:10.1093/ajh/hpaa069 · PMID 32303749 · PMC7402223
5. Journal / agency Barzilay J, Grimm R, Cushman W, Bertoni AG, Basile J. Getting to goal blood pressure: why reserpine deserves a second look. Journal of Clinical Hypertension. August 2007. doi:10.1111/j.1524-6175.2007.07229.x · PMID 17673879 · PMC8110058
6. Journal / agency Wang B, Choudhry NK, Gagne JJ, Landon J, Kesselheim AS. Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. American Heart Journal. March 2015. doi:10.1016/j.ahj.2014.12.014 · PMID 25728728
7. Other Forney, Barbara. Reserpine for Veterinary Use Wedgewood Pharmacy. 2001-2002. link 2
8. Journal / agency Morley JE. Treatment of hypertension in older persons: what is the evidence?. Drugs & Aging. May 2014. doi:10.1007/s40266-014-0171-7 · PMID 24668034
9. Journal / agency Hoenders HJ, Bartels-Velthuis AA, Vollbehr NK, Bruggeman R, Knegtering H, de Jong JT. Natural Medicines for Psychotic Disorders: A Systematic Review. The Journal of Nervous and Mental Disease. February 2018. doi:10.1097/NMD.0000000000000782 · PMID 29373456 · PMC5794244
10. Journal / agency Nur S, Adams CE. Chlorpromazine versus reserpine for schizophrenia. The Cochrane Database of Systematic Reviews. April 2016. doi:10.1002/14651858.CD012122.pub2 · PMID 27124109 · PMC10350329
11. Journal / agency Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. The Cochrane Database of Systematic Reviews. December 2016. doi:10.1002/14651858.CD007655.pub3 · PMID 27997978 · PMC6464022
12. Journal / agency Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. December 1979. doi:10.1001/jama.242.23.2562 · PMID 490882
13. Journal / agency Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. December 1967. doi:10.1001/jama.202.11.1028 · PMID 4862069
14. Journal / agency Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. June 1991. doi:10.1001/jama.265.24.3255 · PMID 2046107
15. Journal / agency ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. December 2002. doi:10.1001/jama.288.23.2981 · PMID 12479763
16. Other Shen, Howard. Illustrated Pharmacology Memory Cards: PharMnemonics. 2008
17. Journal / agency Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgraduate Medical Journal. June 2007. doi:10.1136/pgmj.2006.054759 · PMID 17551069 · PMC2600052
18. Other Forney B. Reserpine for veterinary use. Available at
19. Journal / agency Parai D, Banerjee M, Dey P, Mukherjee SK. Reserpine attenuates biofilm formation and virulence of Staphylococcus aureus. Microbial Pathogenesis. January 2020. doi:10.1016/j.micpath.2019.103790 · PMID 31605761
20. Journal / agency Curb JD, Schneider K, Taylor JO, Maxwell M, Shulman N. Antihypertensive drug side effects in the Hypertension Detection and Follow-up Program. Hypertension. March 1988. doi:10.1161/01.hyp.11.3_pt_2.ii51 · PMID 3350594
21. Other AJ Giannini, HR Black. Psychiatric, Psychogenic, and Somatopsychic Disorders Handbook. Garden City, NY. Medical Examination Publishing, 1978. Pg. 233 ISBN 0-87488-596-5
22. Journal / agency Barcelos RC, Benvegnú DM, Boufleur N, Pase C, Teixeira AM, Reckziegel P, Emanuelli T, da Rocha JB, Bürger ME. Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats. Lipids. February 2011. doi:10.1007/s11745-010-3514-0 · PMID 21161603
23. Other Retrieved on June 19, 2009 Deprecated archive
24. Other Pinel JP. Biopsychology. 2011
25. Journal / agency Yaffe D, Forrest LR, Schuldiner S. The ins and outs of vesicular monoamine transporters. The Journal of General Physiology. May 2018. doi:10.1085/jgp.201711980 · PMID 29666153 · PMC5940252
26. Journal / agency Eiden LE, Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences. January 2011. doi:10.1111/j.1749-6632.2010.05906.x · PMID 21272013 · PMC4183197
27. Journal / agency German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. Pharmacological Reviews. October 2015. doi:10.1124/pr.114.010397 · PMID 26408528 · PMC4630566
28. Journal / agency Stutz PV, Golani LK, Witkin JM. Animal models of fatigue in major depressive disorder. Physiol Behav. February 2019. doi:10.1016/j.physbeh.2018.11.042 · PMID 30513290
29. Journal / agency Salamone JD, Yohn SE, López-Cruz L, San Miguel N, Correa M. Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology. Brain. May 2016. doi:10.1093/brain/aww050 · PMID 27189581 · PMC5839596
30. Other Rauwolfia Dorlands Medical Dictionary. Merck Source. 2002
31. Other Reserpine. 2005
32. Other Pills for Mental Illness?, TIME Magazine, November 8, 1954
33. Other Nicolaou KC, Sorensen EJ. Classics in Total Synthesis. 1996
34. Journal / agency López-Muñoz F, Bhatara VS, Alamo C, Cuenca E. Historical approach to reserpine discovery and its introduction in psychiatry. Actas Españolas de Psiquiatría. 2004. PMID 15529229
35. Journal / agency Everett GM, Toman JE. Mode of action of Rauwolfia alkaloids and motor activity. Biol Psychiat. 1959
36. Other Govindarajulu M. Medicinal herbs and fungi: neurotoxicity vs. neuroprotection. 2021
37. Journal / agency Baumeister AA, Hawkins MF, Uzelac SM. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. Journal of the History of the Neurosciences. June 2003. doi:10.1076/jhin.12.2.207.15535 · PMID 12953623
38. Journal / agency Davies DL, Shepherd M. Reserpine in the treatment of anxious and depressed patients. Lancet. July 1955. doi:10.1016/s0140-6736(55)92118-8 · PMID 14392947
39. Other Healy, David. The Antidepressant Era. 1997
40. Journal / agency Strawbridge R, Javed RR, Cave J, Jauhar S, Young AH. The effects of reserpine on depression: A systematic review. J Psychopharmacol. August 2022. doi:10.1177/02698811221115762 · PMID 36000248 · PMC10076328

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.